ClinicalTrials.Veeva

Menu
The trial is taking place at:
R

Rama Research LLC | Marion, OH

Veeva-enabled site

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Novartis logo

Novartis

Status and phase

Active, not recruiting
Phase 3

Conditions

Atherosclerotic Cardiovascular Disease

Treatments

Drug: Placebo
Drug: Inclisiran sodium 300 mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT05030428
CKJX839B12302

Details and patient eligibility

About

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).

Full description

Purpose of this study is to test the hypothesis that treatment with inclisiran sodium 300 mg s.c. administered on Day 1, Month 3 (Day 90), and every 6 months thereafter taken in addition to well-tolerated high-intensity statin therapy in participants with established ASCVD will significantly reduce the risk of 3-Point-Major Adverse Cardiovascular Events (3P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI) and non-fatal ischemic stroke. This will be compared to placebo in adjunct to well-tolerated high-intensity statin therapy.

Enrollment

17,006 patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Fasting LDL-C ≥ 70 mg/dL at randomization visit

  2. Stable (greater than or equal to 4 weeks) and well-tolerated lipid-lowering regimen (including e.g. with or without Ezetimibe) that must include a high-intensity statin therapy with either atorvastatin greater than or equal to 40 mg QD or rosuvastatin greater than or equal to 20 mg QD

  3. Established CV disease defined as ANY of the following three conditions

    1. Spontaneous Myocardial infarction ≥ 4 weeks from screening visit
    2. History of ischemic stroke occurred ≥ 4 weeks prior to the Screening visit
    3. Symptomatic peripheral arterial disease (PAD) evidenced by either intermittent claudication with ankle brachial index (ABI) < 0.85, prior peripheral arterial revascularization procedure, or, amputation due to atherosclerotic disease.

Exclusion criteria

  1. Acute coronary syndrome, stroke, peripheral arterial revascularization procedure or amputation due to atherosclerotic disease < 4 weeks before screening visit
  2. Treatment with PCSK9 inhibitors (e.g. evolocumab, alirocumab) within 90 days or planned use post first study visit
  3. Planned or expected cardiac, cerebrovascular or peripheral artery surgery or re-vascularization within the 6 months after the first study visit
  4. Heart failure NYHA class III or IV
  5. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver
  6. Previous exposure to inclisiran or any other non-mAb PCSK9-targeted therapy, either as an investigational or marketed drug within 2 years
  7. Severe concomitant non-CV disease that is expected to reduce life expectancy to less than 5 years
  8. History of malignancy that required surgery radiation therapy and/or systemic therapy during the 3 years prior to the first study visit
  9. Pregnant or nursing (lactating) women

Other protocol-defined inclusion/exclusion criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

17,006 participants in 2 patient groups, including a placebo group

Inclisiran sodium
Experimental group
Description:
Subcutaneous injection
Treatment:
Drug: Inclisiran sodium 300 mg
Placebo
Placebo Comparator group
Description:
Subcutaneous injection
Treatment:
Drug: Placebo

Trial contacts and locations

1009

Loading...

Central trial contact

Novartis Pharmaceuticals; Novartis Pharmaceuticals

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems